Hematologic Malignancies
AMA PRA Category 1 Credits 1.00
CAMPEP Credits: 1.00
MDCB Credits: 1.00
Chirayu Patel, MD, MD, MPH
Massachusetts General Hospital
Bellingham, MA, United States
Joachim Yahalom, MD, FASTRO
Memorial Sloan Kettering Cancer Center
New York, New york, United States
Radiotherapy plays an important role as a consolidation treatment after systemic therapy, either to shorten the course of systemic therapy and reduce hematological, cardiac and fertility toxicity or to reduce the risk of relapse e.g., for bulky masses. This role has been challenged in recent years partly due to the hope that PET/CT can select patients who benefit from treatment and reduce the number of patients treated and partly due to exaggerated concern about RT long-term effects which are minimal with modern RT. Several studies have looked at the role of PET in guiding the use of RT with mixed success. In most cases, RT still improved disease control even when PET/CT showed complete response.
However, population-based studies show continuous decline in use of RT in early stage lymphoma, primarily driven by medical oncologists/hematologists attitudes and concerns. In the last year, there have been several important trial reports confirming the role of consolidation RT or providing good evidence on how to select patients for this treatment, which radiation oncologists need to understand well. This session will discuss the most recent evidence published in the last 12 months including H10, IELSG-37 and UNFOLDER studies.
Speaker: Chirayu Patel, MD, MD, MPH – Massachusetts General Hospital
Speaker: Umberto Ricardi, MD, PhD – University of Torino
Speaker: Jessica Brady, MD, MB, ChB – Guy's and St. Thomas' NHS Foundation Trust
Speaker: George Mikhaeel, MD, MBBS – Guy's Cancer Center
Speaker: Joachim Yahalom, MD, FASTRO – Memorial Sloan Kettering Cancer Center
Speaker: Chirayu Patel, MD, MD, MPH – Massachusetts General Hospital